Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...
Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...
Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...
Dawson James Securities slashed its price target for Aditxt Therapeutics (NASDAQ:ADTX) to $1 from $6, but maintained a “buy” rating, noting that cash is tight and a capital raise is expected. The stock closed at 17...
Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...
Dawson James downgraded ProPhase Labs (NASDAQ:PRPH) to “sell” from “neutral” with a price target of $5 after the company announced a license agreement with Global BioLife. Shares of ProPhase were quoted at $11.71, down...
Dawson James lowered its price target for Mesoblast (NASDAQ:MESO) to $7 from $12, but retained its “buy” rating, after the company reported encouraging data from a 565-patient trial in New York Heart Association Class...
Dawson James downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “neutral” from “buy” and removed its price target after a Phase 3 trial investigating muscle regeneration following hip surgery did not meet the primary...
Dawson James halved its price target for Dyadic International (NASDAQ:DYAI) to $3 from $6, citing the company’s C1 platform and whether it will be adopted by a major vaccine maker anytime soon. The stock closed at $2.48...
Dawson James Securities launched coverage of Know Labs (OTCQB:KNWN) with a “buy” rating and price target of $7. The stock closed at $1.59 on Feb. 7. “Know Labs is driving what could be a significant paradigm shift in...